Matinas Biopharma Holdings Net Profit Margin 2012-2025 | MTNB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Matinas Biopharma Holdings net profit margin from 2012 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Matinas Biopharma Holdings net profit margin from 2012 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$81.7B
Zoetis (ZTS)	$66.3B
Daiichi Sankyo, - (DSNKY)	$46.4B
Takeda Pharmaceutical (TAK)	$43.3B
BeOne Medicines - (ONC)	$32.9B
Sandoz Group AG (SDZNY)	$25.9B
Summit Therapeutics (SMMT)	$19.8B
Merck (MKKGY)	$16.5B
Shionogi (SGIOY)	$14.3B
Neurocrine Biosciences (NBIX)	$13.5B
United Therapeutics (UTHR)	$12.7B
Orion OYJ (ORINY)	$11.5B
IPSEN (IPSEY)	$10.8B
Stevanato Group S.p.A (STVN)	$7.6B
Grifols, S.A (GRFS)	$7.5B
Corcept Therapeutics (CORT)	$7.4B
Ionis Pharmaceuticals (IONS)	$6.9B
Madrigal Pharmaceuticals (MDGL)	$6.4B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.3B
Hypermarcas (HYPMY)	$3.1B
Crinetics Pharmaceuticals (CRNX)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
NewAmsterdam Pharma (NAMS)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.2B
Ocular Therapeutix (OCUL)	$1.9B
Endo (NDOI)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.8B